GUTS Fractyl Health, Inc. Common Stock
USHealthcareAs of 2026-07-09 11:25
Why GUTS matters now
Fractyl Health, Inc. Common Stock (GUTS) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.79 with +3.57% on the session and $57.0M in market capitalization; recent performance reads 1-month +5.04% and YTD -60.99%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $9.2M, and EPS of $0.12. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -141.8%.
The latest indexable market news headline is "Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $2.00; recent insider activity includes Royan Ajay filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.04
P/S
0.00
EV/EBITDA
-0.56
DCF Value
$0.24
FCF Yield
-141.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-4573.9%
ROA
-108.7%
ROIC
-104.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $9.2M | $0.12 |
| Q4 2025 | $0.00 | $-43.7M | $-0.58 |
| FY 2025 | $0.00 | $-141.0M | $-1.86 |
| Q3 2025 | $0.00 | $-45.6M | $-0.71 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$2.00
Target (Median)
$2.00
Target Range
$2.00 - $2.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.34
Fractyl Health, Inc. is a biopharmaceutical firm dedicated to advancing treatments for type 2 diabetes (T2D) and obesity. Among its offerings is the Revita DMR System (Revita), an outpatient procedure engineered to provide lasting modification of duodenal dysfunction. This condition often arises from diets high in fat and sugar, playing a role in the onset of T2D and obesity in individuals. Fractyl Health is also pioneering Rejuva, an innovative gene therapy platform utilizing a viral delivery system directly to the pancreas. Rejuva's objective is to achieve long-term remission from T2D and obesity by fundamentally altering metabolic hormone function within patients' pancreatic islet cells. Incorporated in 2010, the company, formerly known as Fractyl Laboratories Inc., officially became Fractyl Health, Inc. on June 9, 2021. Its operations are headquartered in Lexington, Massachusetts.